ETNB - יחס חוב להיוון בספרים 89bio Inc

The 89bio, Inc. (ETNB) price chart on the GURU.Markets platform illustrates the price action of the asset, which is currently valued at 0.07. The business focuses on developing Pegozafermin, an innovative treatment for fatty liver disease based on modified FGF21. The development model anticipates high margins driven by formula patenting, while supply reliability is ensured through the use of specialized cold-chain transportation.

This indicator determines the proportion of borrowed capital relative to the total value of assets minus liabilities, reflecting the extent to which the balance sheet structure depends on credit resources. For 89bio, Inc. (ETNB), the total debt-to-book capitalization ratio serves as a marker of financial stability when scaling operations with external research centers, where an increase in debt may indicate a search for liquidity to diversify the vendor pool.